Sheets Smith Wealth Management’s ImmunityBio IBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.49M Sell
512,572
-39,453
-7% -$299K 0.45% 54
2026
Q1
$4.23M Sell
552,025
-79,950
-13% -$547K 0.48% 53
2025
Q4
$1.25M Sell
631,975
-1,100
-0.2% -$2.49K 0.14% 151
2025
Q3
$1.56M Sell
633,075
-400
-0.1% -$1.03K 0.18% 120
2025
Q2
$1.67M Hold
633,475
0.2% 108
2025
Q1
$1.91M Sell
633,475
-500
-0.1% -$1.51K 0.24% 95
2024
Q4
$1.62M Sell
633,975
-32,020
-5% -$133K 0.2% 113
2024
Q3
$2.48M Hold
665,995
0.3% 79
2024
Q2
$4.21M Sell
665,995
-279,725
-30% -$1.84M 0.5% 53
2024
Q1
$5.08M Buy
945,720
+749,041
+381% +$3.39M 0.57% 42
2023
Q4
$987K Sell
196,679
-77,200
-28% -$242K 0.14% 142
2023
Q3
$463K Buy
273,879
+4,750
+2% +$9.54K 0.07% 208
2023
Q2
$748K Sell
269,129
-1,321,269
-83% -$3.74M 0.11% 164
2023
Q1
$2.89M Buy
1,590,398
+46,350
+3% +$144K 0.44% 54
2022
Q4
$7.83M Buy
1,544,048
+1,336,122
+643% +$7.34M 1.23% 19
2022
Q3
$1.03M Hold
207,926
0.17% 122
2022
Q2
$773K Buy
207,926
+4,050
+2% +$16.3K 0.13% 152
2022
Q1
$1.14M Buy
203,876
+51,600
+34% +$317K 0.16% 129
2021
Q4
$926K Buy
152,276
+30,353
+25% +$228K 0.11% 162
2021
Q3
$1.19M Buy
121,923
+33,770
+38% +$372K 0.16% 133
2021
Q2
$1.26M Buy
88,153
+66,503
+307% +$1.1M 0.17% 127
2021
Q1
$514K Buy
+21,650
New +$561K 0.08% 203

Other funds holding IBRX

Sheets Smith Wealth Management's IBRX Position: Q2 2026 in Review

Sheets Smith Wealth Management reduced its ImmunityBio (IBRX) stake by 7.1% in Q2 2026, selling an estimated $299K and leaving 512,572 shares worth $4.49M. The position accounts for 0.45% of the portfolio, ranked #54.

Sheets Smith Wealth Management first reported a position in IBRX in Q1 2021 and has held it in 22 quarters since. The position peaked at $7.83M in Q4 2022. 48 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Sheets Smith Wealth Management held 512,572 shares of ImmunityBio worth $4.49M as of Q2 2026.
  • Sheets Smith Wealth Management sold 39,453 ImmunityBio shares in Q2 2026, an estimated $299K.
  • ImmunityBio made up 0.45% of Sheets Smith Wealth Management's portfolio in Q2 2026, its #54 holding.
  • Sheets Smith Wealth Management first reported a position in ImmunityBio in Q1 2021 and has held it in 22 quarters since.
  • Sheets Smith Wealth Management's ImmunityBio position peaked at $7.83M in Q4 2022.
  • 48 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Sheets Smith Wealth Management's 13F filing for Q2 2026, filed 13 Jul 2026.